JP Morgan Chase’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-562,108
| Closed | -$8.5M | – | 7339 |
|
|
2022
Q3 | $8.5M | Buy |
562,108
+534,754
| +1,955% | +$6.22M | ﹤0.01% | 2292 |
|
|
2022
Q2 | $205K | Buy |
27,354
+1,453
| +6% | +$10.2K | ﹤0.01% | 5072 |
|
|
2022
Q1 | $236K | Buy |
25,901
+5,089
| +24% | +$39.2K | ﹤0.01% | 5106 |
|
|
2021
Q4 | $146K | Sell |
20,812
-9,293
| -31% | -$97.2K | ﹤0.01% | 5516 |
|
|
2021
Q3 | $344K | Buy |
30,105
+705
| +2% | +$10.3K | ﹤0.01% | 4930 |
|
|
2021
Q2 | $470K | Buy |
29,400
+5,126
| +21% | +$87.9K | ﹤0.01% | 4735 |
|
|
2021
Q1 | $434K | Buy |
24,274
+7,670
| +46% | +$132K | ﹤0.01% | 4759 |
|
|
2020
Q4 | $224K | Buy |
16,604
+2,928
| +21% | +$35.4K | ﹤0.01% | 4774 |
|
|
2020
Q3 | $156K | Buy |
13,676
+1,248
| +10% | +$15.2K | ﹤0.01% | 4484 |
|
|
2020
Q2 | $183K | Sell |
12,428
-1,492
| -11% | -$22.1K | ﹤0.01% | 4307 |
|
|
2020
Q1 | $188K | Sell |
13,920
-66,204
| -83% | -$1.26M | ﹤0.01% | 4294 |
|
|
2019
Q4 | $1.94M | Buy |
80,124
+66,285
| +479% | +$1.37M | ﹤0.01% | 3412 |
|
|
2019
Q3 | $266K | Buy |
13,839
+2,244
| +19% | +$51.4K | ﹤0.01% | 4492 |
|
|
2019
Q2 | $337K | Buy |
11,595
+2,953
| +34% | +$114K | ﹤0.01% | 4421 |
|
|
2019
Q1 | $410K | Sell |
8,642
-444
| -5% | -$19.5K | ﹤0.01% | 4301 |
|
|
2018
Q4 | $328K | Buy |
9,086
+847
| +10% | +$39.7K | ﹤0.01% | 4349 |
|
|
2018
Q3 | $507K | Buy |
8,239
+33
| +0.4% | +$2.12K | ﹤0.01% | 4272 |
|
|
2018
Q2 | $554K | Buy |
8,206
+587
| +8% | +$32.8K | ﹤0.01% | 4124 |
|
|
2018
Q1 | $414K | Sell |
7,619
-11,951
| -61% | -$668K | ﹤0.01% | 4087 |
|
|
2017
Q4 | $1.17M | Buy |
+19,570
| New | +$1.19M | ﹤0.01% | 3635 |
|
|
2017
Q1 | – | Sell |
-38,452
| Closed | -$1.46M | – | 5296 |
|
|
2016
Q4 | $1.46M | Buy |
+38,452
| New | +$1.45M | ﹤0.01% | 3264 |
|
|
2016
Q3 | – | Sell |
-284
| Closed | -$5K | – | 4907 |
|
|
2016
Q2 | $5K | Sell |
284
-312
| -52% | -$5.05K | ﹤0.01% | 4466 |
|
|
2016
Q1 | $7K | Buy |
596
+312
| +110% | +$4.94K | ﹤0.01% | 4322 |
|
|
2015
Q4 | $7K | Buy |
+284
| New | +$6.63K | ﹤0.01% | 4289 |
|
|
2014
Q4 | – | Sell |
-245,733
| Closed | -$5.08M | – | 4411 |
|
|
2014
Q3 | $5.08M | Buy |
+245,733
| New | +$4.85M | ﹤0.01% | 2365 |
|
JP Morgan Chase's AERI Position: Q4 2022 in Review
JP Morgan Chase sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 562,108 shares — an estimated $8.5M sold.
JP Morgan Chase first reported a position in AERI in Q3 2014 and held it in 25 quarters. The position peaked at $8.5M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- JP Morgan Chase reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- JP Morgan Chase sold 562,108 Aerie Pharmaceuticals shares in Q4 2022, an estimated $8.5M.
- JP Morgan Chase first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 25 quarters.
- JP Morgan Chase's Aerie Pharmaceuticals position peaked at $8.5M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.